UK committee demands ‘much-needed clarity’ on UK-US pharma trade deal
The head of a UK government committee has demanded more details on how the country is planning to fund the higher prices it will pay
The head of a UK government committee has demanded more details on how the country is planning to fund the higher prices it will pay
What a year! The XBI is up, M&A is bumping and the vibes are improving. But it ain’t all Christmas cookies. As has become our
Early returns suggest that Takeda’s $4 billion immunology bet appears to be paying off. Takeda said Thursday that its drug zasocitinib succeeded in two Phase
Plus, news on: Orum, FoRx, Gain Therapuetics and Antigenix: 💉 FDA approves injected version of Rybrevant: US regulators cleared a subcutaneous version of the Johnson
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Alnylam Pharmaceuticals is spending $250 million
Moderna has snagged a new partner to help pay for a Phase 3 study of its H5 pandemic influenza vaccine, more than six months after
Steve Paul is back with a fresh take on schizophrenia drugs, co-founding a new biotech called Syremis Therapeutics that’s already landed $165 million in a
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844